1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,570 | 9,800 | 09:53 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2025 | 78 | GlobeNewswire (Europe) | "I took over as the new CEO of Devyser on August 4th and it has been an exciting and eventful time. We are continuing to launch unique products and sign cooperation agreements with major companies in... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 04.11. | Devyser Diagnostics AB: Devyser CFTR achieves IVDR compliance, strengthening clinical confidence in cystic fibrosis diagnostics | 217 | GlobeNewswire (Europe) | Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its next-generation sequencing (NGS) based CFTR assay is now compliant under the European In Vitro Diagnostic Regulation... ► Artikel lesen | |
| 22.09. | Devyser Diagnostics AB: Bulletin from an Extraordinary General Meeting in Devyser Diagnostics AB (publ) held on 22 September 2025 | 103 | GlobeNewswire (Europe) | An Extraordinary General Meeting of Devyser Diagnostics AB (publ) ("Devyser" or the "Company") was held on Monday, 22 September 2025 at Bränningevägen 12, 120 54 Årsta. The main resolution passed at... ► Artikel lesen | |
| 15.08. | Devyser im zweiten Quartal 2025: Umsatz steigt um 27 % bei Rückkehr in die Gewinnzone | 1 | Investing.com Deutsch | ||
| 15.08. | Devyser Q2 2025 presentation: Revenue jumps 27% as profitability returns | 3 | Investing.com | ||
| 22.07. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2025 | 173 | GlobeNewswire (Europe) | "A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs and in the cost... ► Artikel lesen | |
| 30.06. | Devyser Diagnostics AB: Devyser launches Genomic Blood Typing assay: All blood groups, one simple test | 181 | GlobeNewswire (Europe) | Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this... ► Artikel lesen | |
| 29.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 401 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen | |
| 14.04. | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 266 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
| 19.02. | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 266 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| 13.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 402 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 218 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen | |
| 16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 738 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 87,31 | +0,28 % | Opening Bell: Xiaomi, Xpeng, Home Depot, Baidu, Medtronic | Die US-Börsen sind mit Verlusten in die neue Woche gestartet. Der Dow Jones rutschte im Verlauf immer weiter ab und schloss 1,18 Prozent tiefer bei 46.590 Punkten. Zwischenzeitlich hatte der Leitindex... ► Artikel lesen | |
| HCA HEALTHCARE | 411,00 | -0,48 % | HCA HealthONE Rose First in Colorado to Adopt Perimeter's Advanced OCT Imaging Technology for Use in Surgery | ||
| LANTHEUS | 45,940 | -0,58 % | Lantheus Holdings, Inc.: Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update | Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of $94.7 millionSeparately... ► Artikel lesen | |
| ENVISTA | 16,300 | +1,24 % | Envista Holdings Corporation: Envista Reports Third Quarter 2025 Results | BREA, Calif., Oct. 29, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended September 26, 2025."This was another strong quarter... ► Artikel lesen | |
| CAREDX | 13,520 | -0,70 % | CareDx, Inc.: CareDx präsentiert neue IVD-Produkte und IVDR-Zertifizierung für AlloSeq Tx und QTYPE bei der Jahrestagung 2025 der American Society of Histocompatibility & Immunogenetics | Festigung der weltweiten Führungsrolle bei der HLA-Typisierung von Spenderorganen und Transplantatempfängern
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company ein führendes Unternehmen auf dem... ► Artikel lesen | |
| GT BIOPHARMA | 0,590 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Phase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports First Quarter Fiscal Year 2026 Results | Reports 21% Increase in ARR to $21.3 Million, Strong Growth in Net Income, Adjusted EBITDA and Operating Cash Flow
HENDERSON, Nev., Nov. 13, 2025 /PRNewswire/... ► Artikel lesen | |
| CARMAT | 0,099 | -100,00 % | CARMAT Provides an Update on the Ongoing Receivership Procedure | A takeover bid within the context of a sales plan has been received by the judiciary administrator
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced... ► Artikel lesen | |
| CHEMOMETEC | 100,70 | -0,20 % | ChemoMetec stock initiated with Buy rating at Berenberg on CGT growth | ||
| ARRAIL GROUP | 0,189 | +8,00 % | ARRAIL GROUP (06639): POSITIVE PROFIT ALERT | ||
| POLAREAN IMAGING | 0,001 | 0,00 % | Polarean Imaging plans AIM exit as seeks USD20 million funding | ||
| AVEANNA HEALTHCARE | 8,440 | -1,52 % | Aveanna Healthcare Holdings, Inc. - 8-K, Current Report | ||
| LIFESTANCE HEALTH GROUP | 6,200 | -0,88 % | LifeStance Health Group, Inc.: LifeStance Reports Third Quarter 2025 Results | SCOTTSDALE, Ariz., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,500 | -0,17 % | Siemens leitet Trennung von Tochter Healthineers ein - Aktionäre profitieren | Schon vor dem morgigen Kapitalmarkttag von Siemens sind Informationen über die Zukunft der Medizintechnik-Tochter durchgesickert. Das DAX-Schwergewicht will sich mittelfristig von Healthineers trennen.... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 31,540 | +0,57 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen |
Das Unternehmen DEVYSER DIAGNOSTICS AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,040 (+0,41 %) liegt der Kurs bei 9,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.